These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 25651523)

  • 21. Anacetrapib, a cholesteryl ester transfer protein inhibitor.
    Hooper AJ; Burnett JR
    Expert Opin Investig Drugs; 2012 Jan; 21(1):103-9. PubMed ID: 22191425
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetics, metabolism, and excretion of anacetrapib, a novel inhibitor of the cholesteryl ester transfer protein, in rats and rhesus monkeys.
    Tan EY; Hartmann G; Chen Q; Pereira A; Bradley S; Doss G; Zhang AS; Ho JZ; Braun MP; Dean DC; Tang W; Kumar S
    Drug Metab Dispos; 2010 Mar; 38(3):459-73. PubMed ID: 20016052
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Assessment of a pharmacokinetic and pharmacodynamic interaction between simvastatin and anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects.
    Krishna R; Garg A; Jin B; Keshavarz SS; Bieberdorf FA; Chodakewitz J; Wagner JA
    Br J Clin Pharmacol; 2009 May; 67(5):520-6. PubMed ID: 19552746
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identification of a novel, non-tetrahydroquinoline variant of the cholesteryl ester transfer protein (CETP) inhibitor torcetrapib, with improved aqueous solubility.
    Kalgutkar AS; Frederick KS; Hatch HL; Ambler CM; Perry DA; Garigipati RS; Chang GC; Lefker BA; Clark RW; Morehouse LA; Francone O; Hu X
    Xenobiotica; 2014 Jul; 44(7):591-605. PubMed ID: 24380613
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cholesteryl ester transfer protein (CETP) deficiency and CETP inhibitors.
    Mabuchi H; Nohara A; Inazu A
    Mol Cells; 2014 Nov; 37(11):777-84. PubMed ID: 25410905
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Model-based development of anacetrapib, a novel cholesteryl ester transfer protein inhibitor.
    Krishna R; Bergman AJ; Green M; Dockendorf MF; Wagner JA; Dykstra K
    AAPS J; 2011 Jun; 13(2):179-90. PubMed ID: 21347617
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetics and Pharmacodynamics of Anacetrapib in Black and White Healthy Subjects.
    Krishna R; Gheyas F; Corr C; Cote J; Liu Y; Wagner J; Gutstein DE
    J Clin Pharmacol; 2018 Dec; 58(12):1578-1585. PubMed ID: 30029292
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anacetrapib and dalcetrapib differentially alters HDL metabolism and macrophage-to-feces reverse cholesterol transport at similar levels of CETP inhibition in hamsters.
    Briand F; Thieblemont Q; Muzotte E; Burr N; Urbain I; Sulpice T; Johns DG
    Eur J Pharmacol; 2014 Oct; 740():135-43. PubMed ID: 25008069
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety of CETP inhibition.
    Duivenvoorden R; Fayad ZA
    Curr Opin Lipidol; 2012 Dec; 23(6):518-24. PubMed ID: 23010697
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anacetrapib: a potential new therapy for dyslipidemia.
    Robinson LB; Frishman WH
    Cardiol Rev; 2014; 22(5):253-61. PubMed ID: 24618931
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetics and Pharmacodynamics of Anacetrapib Following Single Doses in Healthy, Young Japanese and White Male Subjects.
    Krishna R; Gheyas F; Liu Y; Cote J; Laterza O; Ruckle JL; Wagner JA; Denker AE
    J Clin Pharmacol; 2018 Feb; 58(2):254-262. PubMed ID: 28884824
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anacetrapib and dalcetrapib: two novel cholesteryl ester transfer protein inhibitors.
    Miyares MA
    Ann Pharmacother; 2011 Jan; 45(1):84-94. PubMed ID: 21205945
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lack of an effect of anacetrapib on the pharmacokinetics of digoxin in healthy subjects.
    Krishna R; Stypinski D; Ali M; Garg A; Gendrano IN; Maes A; DeGroot B; Liu Y; Li S; Connolly SM; Wagner JA; Stoch SA
    Biopharm Drug Dispos; 2011 Dec; 32(9):525-9. PubMed ID: 22031172
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of anacetrapib on plasma lipids in specific patient subgroups in the DEFINE (Determining the Efficacy and Tolerability of CETP INhibition with AnacEtrapib) trial.
    Brinton EA; Kher U; Shah S; Cannon CP; Davidson M; Gotto AM; Ashraf TB; McCrary Sisk C; Dansky H; Mitchel Y; Barter P;
    J Clin Lipidol; 2015; 9(1):65-71. PubMed ID: 25670362
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of diltiazem, a moderate CYP3A inhibitor, on the pharmacokinetics of anacetrapib, a potent cholesteryl ester transfer protein inhibitor, in healthy subjects.
    Garg A; Maes A; Corr C; Jin B; Wadhwa T; Handa N; Van Dyck K; De Lepeleire I; Shah J; Wagner JA; Krishna R
    J Clin Pharmacol; 2011 Mar; 51(3):436-9. PubMed ID: 20418508
    [No Abstract]   [Full Text] [Related]  

  • 36. Assessment of the CYP3A-mediated drug interaction potential of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy volunteers.
    Krishna R; Bergman AJ; Jin B; Garg A; Roadcap B; Chiou R; Dru J; Cote J; Laethem T; Wang RW; Didolkar V; Vets E; Gottesdiener K; Wagner JA
    J Clin Pharmacol; 2009 Jan; 49(1):80-7. PubMed ID: 19004846
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anacetrapib as lipid-modifying therapy in patients with heterozygous familial hypercholesterolaemia (REALIZE): a randomised, double-blind, placebo-controlled, phase 3 study.
    Kastelein JJ; Besseling J; Shah S; Bergeron J; Langslet G; Hovingh GK; Al-Saady N; Koeijvoets M; Hunter J; Johnson-Levonas AO; Fable J; Sapre A; Mitchel Y
    Lancet; 2015 May; 385(9983):2153-61. PubMed ID: 25743173
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Multiple-dose pharmacodynamics and pharmacokinetics of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects.
    Krishna R; Bergman AJ; Jin B; Fallon M; Cote J; Van Hoydonck P; Laethem T; Gendrano IN; Van Dyck K; Hilliard D; Laterza O; Snyder K; Chavez-Eng C; Lutz R; Chen J; Bloomfield DM; De Smet M; Van Bortel LM; Gutierrez M; Al-Huniti N; Dykstra K; Gottesdiener KM; Wagner JA
    Clin Pharmacol Ther; 2008 Dec; 84(6):679-83. PubMed ID: 18580870
    [No Abstract]   [Full Text] [Related]  

  • 39. Safety of inhibition of cholesteryl ester transfer protein with anacetrapib: the DEFINE study.
    Gotto AM; Moon JE
    Expert Rev Cardiovasc Ther; 2012 Aug; 10(8):955-63. PubMed ID: 23030283
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anacetrapib, a novel CETP inhibitor: pursuing a new approach to cardiovascular risk reduction.
    Gutstein DE; Krishna R; Johns D; Surks HK; Dansky HM; Shah S; Mitchel YB; Arena J; Wagner JA
    Clin Pharmacol Ther; 2012 Jan; 91(1):109-22. PubMed ID: 22130116
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.